Canadian Center for Vaccinology, IWK Health Centre
Halifax, Nova Scotia, Canada
NCT Number: NCT01273077
Two rotavirus vaccines have been authorized for use in Canada: RotaTeq®, Merck Frost Canada, Inc. and Rotarix®, Glaxo Smith Kline (GSK). In contrast to the United States, Australia and several other western countries, neither rotavirus vaccine is offered in a publicly funded program in Canada. A universal rotavirus immunization program offered to all children has the potential to prevent moderate to severe forms of the disease associated with rotavirus, with associated decreased disease burden and health care costs. This demonstration project seeks to evaluate the effect of the implementation of a universal infant immunization program with Rotarix employing two different program delivery models (public health delivery or physician office delivery) in comparison to a jurisdiction where routine immunization is not provided. Only evaluation of the program will be the subject of this study.
Looking for future studies?
Notify Me6 week and older
All sexes
Observational
Halifax, Nova Scotia, Canada
Rotavirus immunization will be provided as part of the routine, publicly provided immunization program in PEI through Public Health Clinics and in Nova Scotia District Health Authority (DHA) 9 through physicians' offices. Saint John, New Brunswick will act as the control site where no publicly funded immunizations with Rotarix are provided. There are four components to the demonstration project which will take place at each of the three sites: retrospective surveillance, prospective surveillance, a prospective Emergency Department study, and an overall evaluation of the program and its acceptability. Actual provision of the vaccine through a universal immunization program will be undertaken by public health in PEI and in NS DHA 9. The objectives of the rotavirus surveillance (retrospective/prospective) and prospective ED study are:
The objectives for the universal rotavirus immunization program evaluation are:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Rotarix immunization Program:
Inclusion criteria
All infants in Nova Scotia DHA 9 and PEI born between October 1, 2010 and September 30, 2012. 6 weeks to 6 months of age at time of vaccination.
Exclusion:
Retrospective Surveillance (2008-2010)
Inclusion criteria
Exclusion criteria
Prospective surveillance
Inclusion/Exclusion criteria:
Same as listed above for retrospective surveillance except the time period of surveillance will be December 1, 2010 - November 30, 2013.
Safety monitoring Intussusception Surveillance:
Inclusion criteria
Year 1 and 2
1.Invagination of the intestine (intussusception) demonstrated at surgery /2 demonstrated using air or liquid contrast enema 3.An intra-abdominal mass demonstrated using ultrasound or CT scan and was proven to be reduced by hydrostatic enema on a post-reduction imaging 4.Invagination of the intestine (intussusception) demonstrated at autopsy
Exclusion criteria
Emergency Department Rotavirus Snap Shot Study
Inclusion criteria
Year 1
Exclusion criteria
In year 2 and 3 of the project:, systematic stool sampling will be carried out for cases of gastroenteritis in children < 5 years of age presenting to the ED departments.
KAB Questionnaire for Health Care Providers and Parents
Inclusion criteria
Exclusion criteria
•Parents of newborns with a debilitating disease
Time frame: 2 years
Our hypothesis for the first primary objective is that implementation of a universal rotavirus immunization program will result in a decreased burden of disease, as defined by number of hospitalizations in infants under one year of age, due to rotavirus. Evaluation of this objective will consist of the collection and comparison of retrospective and prospective surveillance data.
Time frame: 2 years
We do not have a hypothesis for the second primary objective as it is a descriptive analysis of program implementation.
Dalhousie University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06286865
Digestive System Diseases, Gastrointestinal Diseases
Tromsø, Troms, Norway
View Trial DetailsNCT06159088
Digestive System Diseases, Gastrointestinal Diseases
Jinhua, Zhejiang, China
View Trial DetailsNCT01697397
Colonic Diseases, Colonic Diseases, Functional
Mountain View, California, United States
View Trial DetailsNCT05298774
Digestive System Diseases, Gastrointestinal Diseases
New Haven, Connecticut, United States
View Trial Details